Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

Health officials in Australia have confirmed two more suspected cases of H5 bird flu in migratory birds in Western Australia and New South Wales.

The latest detections take the total number of cases to five in Australia, which is no longer H5-free. The first two cases were reported in Western Australia. The third case of avian influenza was recorded in a giant petrel found at Knights Beach on the Fleurieu Peninsula.

H5 Detected in New South Wales

ABC News reported that samples taken from a giant petrel near Hawks Nest on the NSW Mid North Coast tested positive for the influenza strain in preliminary testing.

NSW Agricultural Minister Tara Moriarty said the bird was wild and had flown in from "other parts of the world" after being identified by a member of the public who noticed it was ill.

"We don't know yet if it is the worst strain of the virus," she said.

Samples from the bird at NSW's Bennetts Beach have been sent to the national testing laboratory in Geelong to determine the strain after being assessed by veterinarians and testing positive for H5 at an agricultural institute in Sydney's Camden.

"We expect to have the results of that at some point tomorrow," Moriarty said.

The NSW Government said it marks the first wild migratory seabird in the state to return a suspected positive result.

Also read: Australia Reports H5 Bird Flu In Second State; Can It Spread to Humans?

H5 Confirmed in Perth

Authorities in Western Australia confirmed H5 in a dead giant petrel found near Mullaloo in Perth's north. It is the first time the infection has been detected in the Perth metropolitan area.

The other WA cases were detected at Quindalup, about 250 kilometres south of Perth, and at Esperance, about 700 kilometes south-east of Perth in the Great Southern region.

Does H5 Have Pandemic Potential?

The NSW Government said that, at this stage, bird flu has not been detected in commercial poultry flocks, captive birds or any other birds in NSW. There is no evidence of mass mortality in wildlife or spread to other animals.

"This strain of avian influenza has had significant impacts overseas, causing widespread mortality in poultry, wild birds and some mammals," it said, urging the public to remain vigilant and report any sick or dead poultry, wild birds or wildlife.

Read More: Australia’s H5N1 Detection Marks End Of Last Virus-Free Continent

Professor of Immunology at Murdoch University Cassandra Berry said the detection of the H5 subtype in Australia "doesn't necessarily mean that the next pandemic has started", newsGP reported.

"Contraction of H5N1 influenza in humans usually requires close contact with sick or dying birds. So, it is cautionary to be alert and stay away from distressed birds," she said.

"Although human-to-human transmission has occurred in other countries, it is rare. Bird-to-human transmission has been associated with a high fatality (~60%). There have been nearly 1,000 cases of human H5N1 infection reported over the last three decades, since H5N1 jumped the species barrier in 1997," the expert said.

GPs Urged to Stay Alert

The Royal Australian College of General Practitioners (RACGP) has urged GPs across Australia to "remain on alert and vigilant of their patients."

The cases mark the first time this H5 subtype (H5N1 clade 2.3.4.4b) has been detected in animals in Australia.

Globally, the subtype has caused mass mortality in poultry, wild birds and sea mammals.

READ: Hantavirus Outbreak Linked To Luxury Cruise Ship Over, Says WHO

The Federal Government and the Australian Centre for Disease Control (CDC) have also updated their advice, while confirming that "the risk to human health remains low."

"Bird flu in people is rare and often mild but can cause severe disease or death. Spread from person-to-person is very rare," the CDC said.

"There have been no human cases of bird flu caused by influenza A virus subtype H5N1 clade 2.3.4.4b in Australia."

RACGP President Dr Michael Wright said it is important that GPs remain vigilant. "Now the virus has arrived, it needs to be put on GPs' radar," he told newsGP. "If you see someone potentially who has been handling these birds, particularly in WA, we need to be on alert."

Symptoms of H5 Bird Flu in Humans

According to the CDC, while some infected people have no symptoms, others may experience:

• Fever
• Cough
• Sore throat
• Runny nose
• Conjunctivitis
• Muscle aches and pains
• Headache
• Fatigue
• Gastrointestinal symptoms

Symptoms can range from mild to severe and usually begin one to 10 days after infection.

People can become infected by breathing in contaminated dust or air, or by touching an infected animal, its body fluids, or contaminated surfaces and then touching their eyes, nose or mouth.

The World Health Organization (WHO) has officially declared the hantavirus outbreak linked to the MV Hondius luxury cruise ship over after the last person being monitored completed quarantine without developing the disease.

Speaking at a media briefing on July 2, WHO Director-General Tedros Adhanom Ghebreyesus said the final person under observation tested negative after completing the recommended 42-day quarantine period for hantavirus exposure.

The individual has since returned home, and no additional infections have been detected since May 25.

"Today, the final contact of a person exposed to #hantavirus on the cruise ship MV Hondius completed their quarantine period, tested negative and returned home. No further cases have been reported since the 25th of May. Therefore, the WHO considers the hantavirus outbreak over," the WHO chief wrote on social media platform X.

The rat-borne virus outbreak infected 13 people and claimed three lives. It was caused by the Andes strain of hantavirus, which carries a risk of human-to-human transmission. There is currently no specific antiviral treatment or vaccine for the virus.

The Dutch-flagged ship departed from Ushuaia, Argentina, on April 1, visiting remote islands in the South Atlantic Ocean, including Tristan da Cunha, before heading to Tenerife in Spain's Canary Islands, where the remaining passengers were evacuated.

Also read: Can Hantavirus Spread Through Semen And Breast Milk? What Experts Say

Over 650 Contacts Traced Across 33 Countries

In an earlier post on X, Dr. Tedros said more than 650 contacts were identified and monitored by health authorities across 33 countries and territories.

"All but 54 contacts have completed their period of quarantine, and the remaining contacts are scheduled to complete their quarantine period by July 2," he told a press conference at WHO headquarters in Geneva.

"If no further cases are reported by then, WHO will consider the outbreak to be over," he added.

The WHO chief said the agency will continue efforts to better understand both the outbreak and the virus.

The UN health agency is working with partners who collected environmental samples from the ship and is coordinating a study among those exposed to better understand how the disease develops.

"We are also working on having a sample of the virus shared with the WHO BioHub in Switzerland," he said.

"This will be important for developing diagnostics, therapeutics, and vaccines for future outbreaks."

CDC Ends US Response

Meanwhile, the US Centers for Disease Control and Prevention (CDC) officially ended its hantavirus outbreak response on June 24.

The agency said none of the 18 Americans who were aboard the cruise ship became ill during the outbreak or the subsequent 42-day incubation period.

"The successful conclusion of this response demonstrates the strength of a coordinated response to infectious disease threats that occur outside of our borders," said CDC Acting Director Jay Bhattacharya in a statement.

"I am grateful for the world-class team at CDC, whose dedication and swift action helped identify potential exposures, provide clear guidance, and protect the American people. As a result, we prevented any new cases from arising in the US."

What Is Hantavirus?

According to the WHO, hantaviruses are zoonotic viruses that naturally infect rodents and are occasionally transmitted to humans.

Globally, an estimated 100,000 to 200,000 hantavirus infections occur each year, with the majority reported in Asia, particularly China. Most cases are sporadic or occur in small clusters linked to contact with infected rodents.

In humans, hantavirus infection can cause severe disease and may be fatal, although the clinical presentation varies depending on the virus strain and geographic region.

How Does Hantavirus Spread?

Hantavirus is primarily spread through contact with infected rodents, including exposure to:

• Urine
• Droppings
• Saliva
• Less commonly, scratches or bites from infected rodents.

Long COVID is a group of debilitating conditions that can persist for months or even years after infection with the SARS-CoV-2 virus, which causes COVID-19.

While scientists are still working to fully define the condition, one of the most common and disabling symptoms is brain fog—a cognitive impairment that can significantly affect people's personal and professional lives.

People with brain fog often report difficulty concentrating, multitasking, reading, remembering information, and speaking in full sentences. Fatigue frequently worsens these symptoms. Despite its widespread impact, there are currently no established diagnostic tests or approved treatments for long COVID-related cognitive impairment.

First Treatment For Brain Fog

A new clinical trial led by researchers at UCL now offers promising evidence that cognitive rehabilitation may provide lasting relief for these symptoms.

Published in JAMA Network Open, the study found that a 10-week cognitive rehabilitation program helped people with long COVID-related brain fog achieve meaningful improvements in returning to work, hobbies, and everyday activities.

The treatment consisted of weekly one-hour, one-to-one video sessions with a therapist who helped participants develop practical strategies to meet their personal rehabilitation goals. Most participants continued to benefit from the program for at least six months after treatment.

Also read: Natural Origin or Lab Leak? Gabbard Reignites COVID Origins Debate, Claims Fauci Funded Wuhan Lab Research

"As many as one in three people with COVID go on to develop long COVID, and cognitive difficulties are among the most common symptoms that can persist for months, disrupting day-to-day functioning and quality of life. People might find it hard to focus or hold on to their thoughts as they struggle with memory, attention and planning, often compounded by fatigue," said lead author Dr Martina Vanova, who completed the research at UCL before moving to Kingston University.

"In our study, we used well-established strategies of goal-oriented cognitive rehabilitation to help people develop ways to tackle the challenges that are most meaningful to them," Vanova added.

How Was The Study Conducted?

Read More: 1 in 6 Americans May Be Suffering From Long COVID, Study Finds

The study, funded by the National Institute for Health and Care Research (NIHR), included 78 participants in England who had experienced cognitive symptoms of long COVID for at least three months.

Half of the participants received the cognitive rehabilitation program, while the other half continued with standard NHS care, which varied by region.

Before treatment began, each participant completed an online goal-setting interview to identify three personal goals they wanted to achieve. Most goals focused on returning to work and improving job performance, while others involved everyday activities such as staying focused long enough to watch a full film or read a book.

Therapists then worked with participants to develop personalized strategies to help them achieve those goals.

What Did the Study Find?

Read: COVID-19 Vaccination Reduced Risk of Heart Attacks and Strokes in Elderly by 40%: Study

Three months after completing treatment, 84% of participants who received cognitive rehabilitation reported a significant improvement in goal attainment on a 10-point scale, compared with 53% of those receiving standard care.

The benefits were sustained over time. After six months, 53% of participants in the rehabilitation group reported a substantial improvement—defined as an increase of four or more points on the 10-point goal scale—compared with just 15% of those in the control group.

Researchers also observed measurable improvements in executive function, including better cognitive flexibility and faster processing speed.

Researchers also noted that early findings from a separate analysis suggest the program is cost-effective.

"We have found a treatment that provides clinically meaningful and sustained benefit for people with cognitive long COVID symptoms," said Joint senior author Dr Aida Suarez-Gonzalez of the UCL Queen Square Institute of Neurology.

"As this program is based on established cognitive rehabilitation techniques that have been used for other conditions, we hope that it can be easily rolled out as a treatment option for people currently living with long COVID."